All News

Chimeric antigen receptor (CAR)-T cell therapy is becoming more widely available, with two drugs approved to treat specific blood cancers and more being investigated in clinical trials across cancer types. Here’s what patients need to know if they’re considering treatment with one of these novel immunotherapies.

The reduced incidence in developing advanced cancer in patients at least 50 years and older was more prominent in those with normal weight vs. overweight or obesity.

Your cancer story is unique to you, but sometimes the impact of sharing it can change your own perspective on the cancer journey.

An artificial intelligence-based algorithm within the electronic medical record provided real-time and accurate predictions of the short-term mortality rate of patients with cancer, outperforming all other prognostic incidences commonly used.

Safety and efficacy observed in this real-world study for patients with non-Hodgkin lymphoma similarly reflect findings from previous pivotal trials.

A two-time cancer survivor loses her wonderful dog to, of course, cancer and offers advice to avoid some pet cancer pitfalls.

A novel type of immunotherapy known as chimeric antigen receptor, or CAR, T cell therapy is a hot topic in the news and in the lab. But what does this treatment consist of, and how was it developed?

Study results also determined that immune system status before treatment may predict outcomes post-treatment.

The drug has been approved to treat patients with advanced or metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer.

Predicting risk for recurrence and progression in patients with nonmuscle-invasive bladder cancer may help when discussing management options with clinicians.

The radioactive diagnostic agent, Gallium 68 PSMA-11, can detect suspected prostate cancer metastasis or recurrence, providing another imaging option for these patients.

The holidays are different this year for everyone, but for patients with cancer and cancer survivors, the holidays in 2020 are a unique challenge that presents difficult thoughts to contemplate.

Machine learning may be used to predict disease progression in patients with advanced melanoma.

Each month, we take a look back at the most popular CURE® stories. Here are the top five stories for November 2020.

Several factors may lead to prolonged treatment duration for breast cancer including socioeconomic status, race, and barriers to care.

On social media, in honor of Thanksgiving, CURE® recently asked its readers to share what they are most thankful for this holiday season.

A cancer survivor shares some ways she coped when confronted with her cancer diagnosis.

Often, patients with cancer will come into contact with only a handful of members of their care team: a primary care physician or oncologist, perhaps a nurse or two. But as Dr. Phillip J. Koo explained, it helps to view the cancer care team – including those who a patient may never see – with a wider lens.

A patient with cancer discusses how the compassionate and encouraging presence of oncology nurses makes a difference in their cancer journey.

A lighthearted look from one cancer survivor on the phrases that we've learned of, or made up, during the COVID-19 pandemic.

Patients with cancer discuss how compassionate and professional oncology nurses make all the difference on their care teams as they go through the cancer journey.

A cancer survivor describes how her oncology nurse was by her side through her cancer journey as both a nurse, and her friend.

An oncology nurse recounts how her fellow nurses are compassionate, empathetic and knowledgeable towards patients with cancer.

Women with breast cancer who undergo fertility preservation with breast cancer are more likely to give birth than those who do not, researchers report.

My grandpa always lived life to the fullest, until the day he couldn't. And while he did, he didn't have to know about my cancer diagnosis.

From the National Cancer Institute releasing promising research data into the genomic mutations that helped “exceptional responders” survive on treatment when others didn’t, to a 15-year-old Kentucky cancer survivor dying from COVID-19, here’s what’s happening in the cancer landscape this week.

Adjusting to the unique holiday season amid the COVID-19 pandemic, all while going through treatment for cancer requires extra kindness and willingness to change some habits. Here are 4 tips to do just that.

Here is a list of some recent trials that launched within the cancer space in November.

The Food and Drug Administration’s approval of Danyelza comes as a result of two trials that assessed the efficacy of the drug in patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow who did not have sufficient response to prior therapies.

This survival benefit was particularly observed in patients with node-positive disease, or cancer that spread to the lymph nodes according to pathology.